Literature DB >> 27324403

Sugammadex: A Review of Neuromuscular Blockade Reversal.

Gillian M Keating1.   

Abstract

Sugammadex (Bridion(®)) is a modified γ-cyclodextrin that reverses the effect of the steroidal nondepolarizing neuromuscular blocking agents rocuronium and vecuronium. Intravenous sugammadex resulted in rapid, predictable recovery from moderate and deep neuromuscular blockade in patients undergoing surgery who received rocuronium or vecuronium. Recovery from moderate neuromuscular blockade was significantly faster with sugammadex 2 mg/kg than with neostigmine, and recovery from deep neuromuscular blockade was significantly faster with sugammadex 4 mg/kg than with neostigmine or spontaneous recovery. In addition, recovery from neuromuscular blockade was significantly faster when sugammadex 16 mg/kg was administered 3 min after rocuronium than when patients spontaneously recovered from succinylcholine. Sugammadex also demonstrated efficacy in various special patient populations, including patients with pulmonary disease, cardiac disease, hepatic dysfunction or myasthenia gravis and morbidly obese patients. Intravenous sugammadex was generally well tolerated. In conclusion, sugammadex is an important option for the rapid reversal of rocuronium- or vecuronium-induced neuromuscular blockade.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27324403     DOI: 10.1007/s40265-016-0604-1

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  71 in total

1.  Use of sugammadex in patients with a history of pulmonary disease.

Authors:  Rasheed Amao; Mark H Zornow; Robert McTaggart Cowan; Davy C Cheng; Jovino B Morte; Martin W Allard
Journal:  J Clin Anesth       Date:  2012-06       Impact factor: 9.452

2.  Sugammadex is cleared rapidly and primarily unchanged via renal excretion.

Authors:  Pierre Peeters; Paul Passier; Jean Smeets; Alex Zwiers; Marcel de Zwart; Saskia van de Wetering-Krebbers; Marlou van Iersel; Sjoerd van Marle; Diels van den Dobbelsteen
Journal:  Biopharm Drug Dispos       Date:  2011-03-01       Impact factor: 1.627

3.  First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.

Authors:  Francois Gijsenbergh; Steven Ramael; Natalie Houwing; Thijs van Iersel
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

4.  Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent.

Authors:  Koen Suy; Karl Morias; Guy Cammu; Pol Hans; Wilbert G F van Duijnhoven; Marten Heeringa; Ignace Demeyer
Journal:  Anesthesiology       Date:  2007-02       Impact factor: 7.892

5.  A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.

Authors:  G Geldner; M Niskanen; P Laurila; V Mizikov; M Hübler; G Beck; H Rietbergen; E Nicolayenko
Journal:  Anaesthesia       Date:  2012-06-14       Impact factor: 6.955

6.  Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.

Authors:  Christopher Rex; Stefanie Wagner; Claudia Spies; Jens Scholz; Henk Rietbergen; Marten Heeringa; Hinnerk Wulf
Journal:  Anesthesiology       Date:  2009-07       Impact factor: 7.892

7.  Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.

Authors:  Karin S Khuenl-Brady; Magnus Wattwil; Bernard F Vanacker; José I Lora-Tamayo; Henk Rietbergen; José A Alvarez-Gómez
Journal:  Anesth Analg       Date:  2009-08-27       Impact factor: 5.108

8.  Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.

Authors:  Yoshifumi Kotake; Ryoichi Ochiai; Takahiro Suzuki; Setsuro Ogawa; Shunichi Takagi; Makoto Ozaki; Itsuo Nakatsuka; Junzo Takeda
Journal:  Anesth Analg       Date:  2013-06-11       Impact factor: 5.108

9.  Sugammadex allows fast-track bariatric surgery.

Authors:  Michele Carron; Stefano Veronese; Mirto Foletto; Carlo Ori
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

10.  Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients: a prospective observational study.

Authors:  G Cammu; D Coart; K De Graeve; R Beelen
Journal:  Acta Anaesthesiol Belg       Date:  2012
View more
  18 in total

Review 1.  Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.

Authors:  Ana-Marija Hristovska; Patricia Duch; Mikkel Allingstrup; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2017-08-14

2.  Neuromuscular Block and Blocking Agents in 2018.

Authors:  Christoph Unterbuchner
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-04-01

3.  Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine.

Authors:  Guang-Dan Zhu; Eric Dawson; Angela Huskey; Ronald J Gordon; Andria L Del Tredici
Journal:  Pharmgenomics Pers Med       Date:  2020-09-30

4.  Sugammadex-Induced Hypersensitivity Reaction in a Pediatric Patient.

Authors:  Alkin Çolak; Elif Yılmaz; Büşra Küçük Kıray
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-02-01

Review 5.  [Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].

Authors:  C Unterbuchner; K Ehehalt; B Graf
Journal:  Anaesthesist       Date:  2019-11       Impact factor: 1.041

6.  Potentiation of Rocuronium Bromide by Lithium Carbonate: A Case Report.

Authors:  Naotaka Kishimoto; Hiroyuki Yoshikawa; Kenji Seo
Journal:  Anesth Prog       Date:  2020-09-01

Review 7.  Tracheal intubation in critically ill patients: a comprehensive systematic review of randomized trials.

Authors:  Luca Cabrini; Giovanni Landoni; Martina Baiardo Redaelli; Omar Saleh; Carmine D Votta; Evgeny Fominskiy; Alessandro Putzu; Cézar Daniel Snak de Souza; Massimo Antonelli; Rinaldo Bellomo; Paolo Pelosi; Alberto Zangrillo
Journal:  Crit Care       Date:  2018-01-20       Impact factor: 9.097

Review 8.  Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents.

Authors:  Yong Beom Kim; Tae-Yun Sung; Hong Seuk Yang
Journal:  Korean J Anesthesiol       Date:  2017-09-28

9.  Comparison of deep or moderate neuromuscular blockade for thoracoscopic lobectomy: a randomized controlled trial.

Authors:  Xiao-Feng Zhang; De-Yuan Li; Jing-Xiang Wu; Qi-Liang Jiang; Hong-Wei Zhu; Mei-Ying Xu
Journal:  BMC Anesthesiol       Date:  2018-12-21       Impact factor: 2.217

10.  Comparison of emergence agitation between succinylcholine and rocuronium-sugammadex in adults following closed reduction of a nasal bone fracture: a prospective randomized controlled trial.

Authors:  Seok-Jin Lee; Tae-Yun Sung; Choon-Kyu Cho
Journal:  BMC Anesthesiol       Date:  2019-12-16       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.